Previous studies showed that the most common EGFR mutations in NSCLC were exon-19 deletions and point mutation L858R in exon-21, which were referred to as sensitive mutations and benefited from RGFR-TKIs' therapy [16]. Here, EGFR is linked to non-small cell lung carcinoma.